首页 > 最新文献

Journal of Pharmaceutical Health Care and Sciences最新文献

英文 中文
Hyperkalemic effect of drug-drug interaction between esaxerenone and trimethoprim in patients with hypertension: a pilot study. 高血压患者服用艾沙塞酮和三甲氧苄氨嘧啶时药物间相互作用的高血钾效应:一项试验研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-02 DOI: 10.1186/s40780-024-00366-6
Toshinori Hirai, Shun Ueda, Toru Ogura, Kan Katayama, Kaoru Dohi, Yuki Kondo, Yuka Sakazaki, Yoichi Ishitsuka, Takuya Iwamoto

Background: We examined whether the pharmacodynamic drug-drug interaction between esaxerenone and trimethoprim enhances the hyperkalemic effect.

Methods: A retrospective observational study was conducted to identify patients >18 years undertaking esaxerenone alone or esaxerenone plus trimethoprim at Mie University Hospital from May 2019 to December 2022. We performed propensity score-matching (1:1) to compare between-group differences in the maximum change in serum potassium levels (ΔK) using the Mann-Whitney U test. For esaxerenone plus trimethoprim, Spearman's correlation coefficients were used to examine correlations between ΔK and variables, including changes in blood urea nitrogen (ΔBUN), serum creatinine levels (ΔCr), and weekly trimethoprim cumulative dose.

Results: Out of propensity score-matched groups (n=8 each), serum potassium levels significantly increased after administration of esaxerenone alone (4.4 [4.2 to 4.7] meq/L to 5.2 [4.7 to 5.4] meq/L, p=0.008) and esaxerenone plus trimethoprim (4.2 [4.0 to 5.1] meq/L to 5.4 [4.7 to 5.5] meq/L, p=0.023). ΔK did not significantly differ between the groups (esaxerenone alone; 0.6 [0.3 to 0.9] meq/L vs. esaxerenone plus trimethoprim; 1.0 [0.4 to 1.3] meq/L, p=0.342). ΔK positively correlated with ΔBUN (r=0.988, p<0.001) or ΔCr (r=0.800, p=0.017). There was a trend of correlation of ΔK with a weekly cumulative trimethoprim dose (r=0.607, p=0.110).

Conclusions: The hyperkalemic effect of the drug-drug interaction between esaxerenone and trimethoprim is not notable and related to renal function and trimethoprim dosage.

背景:我们研究了埃沙塞酮和曲美普林的药效学相互作用是否会增强高钾血症效应:我们研究了埃沙塞酮与曲美普林之间的药效学药物相互作用是否会增强高钾血症效应:我们开展了一项回顾性观察研究,以识别2019年5月至2022年12月期间在三重大学医院接受单独使用埃沙塞酮或埃沙塞酮联合曲美普林治疗的年龄大于18岁的患者。我们进行了倾向得分匹配(1:1),使用 Mann-Whitney U 检验比较了血清钾水平最大变化(ΔK)的组间差异。对于埃沙塞酮加三甲氧苄氨嘧啶,采用斯皮尔曼相关系数检验ΔK与变量之间的相关性,包括血尿素氮(ΔBUN)、血清肌酐水平(ΔCr)和每周三甲氧苄氨嘧啶累积剂量的变化:结果:在倾向评分匹配组(每组 8 人)中,单用艾塞瑞酮(4.4 [4.2 至 4.7] meq/L 至 5.2 [4.7 至 5.4] meq/L,p=0.008)和艾塞瑞酮加曲美普林(4.2 [4.0 至 5.1] meq/L 至 5.4 [4.7 至 5.5] meq/L,p=0.023)后血清钾水平显著升高。各组间的ΔK无明显差异(单用埃沙塞伦龙;0.6 [0.3 至 0.9] meq/L 与埃沙塞伦龙加三甲氧苄啶;1.0 [0.4 至 1.3] meq/L,p=0.342)。ΔK与ΔBUN呈正相关(r=0.988,p结论:埃沙塞酮与曲美布汀之间的药物相互作用所产生的高钾血症效应并不明显,且与肾功能和曲美布汀的剂量有关。
{"title":"Hyperkalemic effect of drug-drug interaction between esaxerenone and trimethoprim in patients with hypertension: a pilot study.","authors":"Toshinori Hirai, Shun Ueda, Toru Ogura, Kan Katayama, Kaoru Dohi, Yuki Kondo, Yuka Sakazaki, Yoichi Ishitsuka, Takuya Iwamoto","doi":"10.1186/s40780-024-00366-6","DOIUrl":"10.1186/s40780-024-00366-6","url":null,"abstract":"<p><strong>Background: </strong>We examined whether the pharmacodynamic drug-drug interaction between esaxerenone and trimethoprim enhances the hyperkalemic effect.</p><p><strong>Methods: </strong>A retrospective observational study was conducted to identify patients >18 years undertaking esaxerenone alone or esaxerenone plus trimethoprim at Mie University Hospital from May 2019 to December 2022. We performed propensity score-matching (1:1) to compare between-group differences in the maximum change in serum potassium levels (ΔK) using the Mann-Whitney U test. For esaxerenone plus trimethoprim, Spearman's correlation coefficients were used to examine correlations between ΔK and variables, including changes in blood urea nitrogen (ΔBUN), serum creatinine levels (ΔCr), and weekly trimethoprim cumulative dose.</p><p><strong>Results: </strong>Out of propensity score-matched groups (n=8 each), serum potassium levels significantly increased after administration of esaxerenone alone (4.4 [4.2 to 4.7] meq/L to 5.2 [4.7 to 5.4] meq/L, p=0.008) and esaxerenone plus trimethoprim (4.2 [4.0 to 5.1] meq/L to 5.4 [4.7 to 5.5] meq/L, p=0.023). ΔK did not significantly differ between the groups (esaxerenone alone; 0.6 [0.3 to 0.9] meq/L vs. esaxerenone plus trimethoprim; 1.0 [0.4 to 1.3] meq/L, p=0.342). ΔK positively correlated with ΔBUN (r=0.988, p<0.001) or ΔCr (r=0.800, p=0.017). There was a trend of correlation of ΔK with a weekly cumulative trimethoprim dose (r=0.607, p=0.110).</p><p><strong>Conclusions: </strong>The hyperkalemic effect of the drug-drug interaction between esaxerenone and trimethoprim is not notable and related to renal function and trimethoprim dosage.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"46"},"PeriodicalIF":1.2,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11295366/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141875067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A retrospective study examining the association between polypharmacy and complications after laparoscopic surgery for colorectal cancer. 一项回顾性研究,探讨多药治疗与腹腔镜结直肠癌手术后并发症之间的关系。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-02 DOI: 10.1186/s40780-024-00369-3
Takashi Watanabe, Shota Kashiwagura, Ryusuke Ouchi, Kensuke Usui, Chikashi Shibata, Kouji Okada

Background: Polypharmacy is an escalating public health concern across various healthcare settings worldwide. We aimed to comprehensively investigate postoperative complications after laparoscopic surgery for colorectal cancer and explore their association with polypharmacy. As laparoscopic surgery is widespread, clarifying the association between polypharmacy and postoperative complications is clinically important.

Methods: We retrospectively surveyed the medical charts of adult inpatients who underwent laparoscopic surgery for colorectal cancer at Tohoku Medical and Pharmaceutical University Hospital between April 2019 and March 2023. Postoperative complications were determined using the Clavien-Dindo classification. We explored the factors related to postoperative complications and calculated the cut-off values for the number of medication ingredients.

Results: Among the 236 patients, 32 (13.6%) developed postoperative complications. On multivariable logistic regression analysis, the number of regularly used medication ingredients (odds ratio = 1.160, 95% confidence interval 1.050-1.270, p = 0.002) was identified as a factor related to postoperative complications. The identified cut-off value for complications was 10 ingredients. Patients using 10 or more ingredients had approximately 3.5 times higher occurrence of postoperative complications than those using fewer than 10 ingredients (33.3% vs. 9.3%, p < 0.001, Fisher's exact test).

Conclusions: Our study comprehensively investigated postoperative complications and examined their association with polypharmacy. We found that the number of regularly used medication ingredients may be linked to complications following laparoscopic surgery for colorectal cancer. These findings have important implications for perioperative management and patient care, providing valuable insights that may influence clinical practices and enhance patient outcomes.

背景:在全球各种医疗机构中,多重用药是一个日益严重的公共卫生问题。我们旨在全面调查腹腔镜结直肠癌手术后的并发症,并探讨其与多重用药的关系。随着腹腔镜手术的广泛开展,明确多药治疗与术后并发症之间的关系在临床上具有重要意义:我们回顾性调查了2019年4月至2023年3月期间在东北医科大学附属药科大学医院接受腹腔镜结直肠癌手术的成年住院患者的病历。术后并发症采用 Clavien-Dindo 分类法确定。我们探讨了与术后并发症相关的因素,并计算了药物成分数量的临界值:在 236 名患者中,32 人(13.6%)出现了术后并发症。在多变量逻辑回归分析中,经常使用的药物成分数量(几率比=1.160,95%置信区间1.050-1.270,P=0.002)被确定为术后并发症的相关因素。确定并发症的临界值为 10 种成分。使用 10 种或更多成分的患者的术后并发症发生率比使用少于 10 种成分的患者高出约 3.5 倍(33.3% 对 9.3%,P 结论:我们的研究全面调查了术后并发症,并研究了其与多种药物的关系。我们发现,经常使用的药物成分数量可能与结直肠癌腹腔镜手术后并发症有关。这些发现对围术期管理和患者护理具有重要意义,提供了可能影响临床实践和改善患者预后的宝贵见解。
{"title":"A retrospective study examining the association between polypharmacy and complications after laparoscopic surgery for colorectal cancer.","authors":"Takashi Watanabe, Shota Kashiwagura, Ryusuke Ouchi, Kensuke Usui, Chikashi Shibata, Kouji Okada","doi":"10.1186/s40780-024-00369-3","DOIUrl":"10.1186/s40780-024-00369-3","url":null,"abstract":"<p><strong>Background: </strong>Polypharmacy is an escalating public health concern across various healthcare settings worldwide. We aimed to comprehensively investigate postoperative complications after laparoscopic surgery for colorectal cancer and explore their association with polypharmacy. As laparoscopic surgery is widespread, clarifying the association between polypharmacy and postoperative complications is clinically important.</p><p><strong>Methods: </strong>We retrospectively surveyed the medical charts of adult inpatients who underwent laparoscopic surgery for colorectal cancer at Tohoku Medical and Pharmaceutical University Hospital between April 2019 and March 2023. Postoperative complications were determined using the Clavien-Dindo classification. We explored the factors related to postoperative complications and calculated the cut-off values for the number of medication ingredients.</p><p><strong>Results: </strong>Among the 236 patients, 32 (13.6%) developed postoperative complications. On multivariable logistic regression analysis, the number of regularly used medication ingredients (odds ratio = 1.160, 95% confidence interval 1.050-1.270, p = 0.002) was identified as a factor related to postoperative complications. The identified cut-off value for complications was 10 ingredients. Patients using 10 or more ingredients had approximately 3.5 times higher occurrence of postoperative complications than those using fewer than 10 ingredients (33.3% vs. 9.3%, p < 0.001, Fisher's exact test).</p><p><strong>Conclusions: </strong>Our study comprehensively investigated postoperative complications and examined their association with polypharmacy. We found that the number of regularly used medication ingredients may be linked to complications following laparoscopic surgery for colorectal cancer. These findings have important implications for perioperative management and patient care, providing valuable insights that may influence clinical practices and enhance patient outcomes.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"47"},"PeriodicalIF":1.2,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11297590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141878925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotic therapy for bacterial pneumonia. 细菌性肺炎的抗生素治疗。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-30 DOI: 10.1186/s40780-024-00367-5
Hideo Kato

Pneumonia is a common infection in patients of all ages. Determining its etiology and selecting antibiotic therapy are challenging for physicians in both private practice and hospitals. Moreover, the coronavirus disease pandemic revealed the importance of prevention and treatment of secondary bacterial pneumonia in patients hospitalized with viral respiratory infections. This review focuses on the types of bacteria that cause pneumonia and provides new insights into antibiotic therapy for bacterial pneumonia. Moreover, it also reviews the current state of knowledge regarding secondary bacterial pneumonia.

肺炎是所有年龄段病人的常见感染。对于私人诊所和医院的医生来说,确定病因和选择抗生素治疗都具有挑战性。此外,冠状病毒疾病大流行揭示了预防和治疗因病毒性呼吸道感染住院患者继发细菌性肺炎的重要性。本综述重点介绍了导致肺炎的细菌类型,并对细菌性肺炎的抗生素治疗提出了新的见解。此外,它还回顾了有关继发性细菌性肺炎的知识现状。
{"title":"Antibiotic therapy for bacterial pneumonia.","authors":"Hideo Kato","doi":"10.1186/s40780-024-00367-5","DOIUrl":"10.1186/s40780-024-00367-5","url":null,"abstract":"<p><p>Pneumonia is a common infection in patients of all ages. Determining its etiology and selecting antibiotic therapy are challenging for physicians in both private practice and hospitals. Moreover, the coronavirus disease pandemic revealed the importance of prevention and treatment of secondary bacterial pneumonia in patients hospitalized with viral respiratory infections. This review focuses on the types of bacteria that cause pneumonia and provides new insights into antibiotic therapy for bacterial pneumonia. Moreover, it also reviews the current state of knowledge regarding secondary bacterial pneumonia.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"45"},"PeriodicalIF":1.2,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemiluminescence method for evaluating photooxidative degradation of dispensed drugs: a potential new drug information tool. 评估配药光氧化降解的化学发光法:一种潜在的新药物信息工具。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-24 DOI: 10.1186/s40780-024-00365-7
Yuriko Murai, Kasumi Kudo, Hiroyuki Suzuki, Taisuke Konno, Yasuyuki Agatsuma, Hitoshi Nakamura

Background: Dispensed drugs stored by patients are often in single-dose packages (SDPs) or are crushed and mixed after being removed from a press-through package (PTP) sheet. Information on their stability is extremely limited. To address this, we explored using chemiluminescence (CL) measurements to detect oxidative degradation.

Methods: Eight amlodipine, 14 telmisartan, and two warfarin preparations were used as specimens. These preparations were stored at room temperature under various conditions, after which CL was measured. Cellopoly packaging paper was used for SDP. Three light conditions were used (Condition A: darkness, Condition B: indoor diffused light (approximately 400 lx), and Condition C: exposure to 4,000 lx). CL cumulative light output was measured every minute under nitrogen gas conduction and with a sample chamber temperature of 150 °C, for a maximum of 10 min. Luminescence images were obtained simultaneously with the CL measurements.

Results: CL was observed on light-exposed tablet surfaces. For each preparation, an increase in the CL value was observed with the duration of light exposure. In the same preparation with the same exposure time, CL tended to be higher in the order of Condition A < B < C. Moreover, CL increased even when no changes in color were observed by the naked eye. A comparison between preparations with the same main ingredients showed differences in the rate of increase in CL with exposure, and each was found to show a different reactivity to light.

Conclusions: To the best of our knowledge, this is the first study to visually capture the surface oxidation of tablets exposed to light using the CL method. The CL values, thought to be derived from photooxidation, increased with exposure of tablets and powders to light after SDP. This method can sensitively assess drug degradation due to photooxidation. Further research is needed to establish a CL method for assessing the stability of preparations in clinical settings.

背景:患者储存的配药通常采用单剂量包装(SDP),或从压穿式包装(PTP)纸上取下后进行粉碎和混合。有关其稳定性的信息极为有限。为了解决这个问题,我们探索使用化学发光(CL)测量方法来检测氧化降解:方法:以 8 种氨氯地平、14 种替米沙坦和 2 种华法林制剂为样本。将这些制剂在室温下以不同条件保存,然后测量其化学光度。SDP 使用 Cellopoly 包装纸。使用了三种光照条件(条件 A:黑暗;条件 B:室内散射光(约 400 lx);条件 C:暴露于 4,000 lx)。在氮气传导和样品室温度为 150 °C 的条件下,每分钟测量一次 CL 累积光输出,最长持续 10 分钟。发光图像与 CL 测量同时进行:在光暴露的药片表面观察到了 CL。在每种制剂中,CL 值都随着光照射时间的延长而增加。在相同曝光时间的同一种制剂中,CL 值往往依次高于条件 A:据我们所知,这是第一项使用 CL 法直观捕捉药片在光照下表面氧化情况的研究。认为源自光氧化的 CL 值随着片剂和粉末在 SDP 后暴露于光线下而增加。这种方法可以灵敏地评估光氧化引起的药物降解。要建立一种用于评估临床制剂稳定性的 CL 方法,还需要进一步的研究。
{"title":"Chemiluminescence method for evaluating photooxidative degradation of dispensed drugs: a potential new drug information tool.","authors":"Yuriko Murai, Kasumi Kudo, Hiroyuki Suzuki, Taisuke Konno, Yasuyuki Agatsuma, Hitoshi Nakamura","doi":"10.1186/s40780-024-00365-7","DOIUrl":"10.1186/s40780-024-00365-7","url":null,"abstract":"<p><strong>Background: </strong>Dispensed drugs stored by patients are often in single-dose packages (SDPs) or are crushed and mixed after being removed from a press-through package (PTP) sheet. Information on their stability is extremely limited. To address this, we explored using chemiluminescence (CL) measurements to detect oxidative degradation.</p><p><strong>Methods: </strong>Eight amlodipine, 14 telmisartan, and two warfarin preparations were used as specimens. These preparations were stored at room temperature under various conditions, after which CL was measured. Cellopoly packaging paper was used for SDP. Three light conditions were used (Condition A: darkness, Condition B: indoor diffused light (approximately 400 lx), and Condition C: exposure to 4,000 lx). CL cumulative light output was measured every minute under nitrogen gas conduction and with a sample chamber temperature of 150 °C, for a maximum of 10 min. Luminescence images were obtained simultaneously with the CL measurements.</p><p><strong>Results: </strong>CL was observed on light-exposed tablet surfaces. For each preparation, an increase in the CL value was observed with the duration of light exposure. In the same preparation with the same exposure time, CL tended to be higher in the order of Condition A < B < C. Moreover, CL increased even when no changes in color were observed by the naked eye. A comparison between preparations with the same main ingredients showed differences in the rate of increase in CL with exposure, and each was found to show a different reactivity to light.</p><p><strong>Conclusions: </strong>To the best of our knowledge, this is the first study to visually capture the surface oxidation of tablets exposed to light using the CL method. The CL values, thought to be derived from photooxidation, increased with exposure of tablets and powders to light after SDP. This method can sensitively assess drug degradation due to photooxidation. Further research is needed to establish a CL method for assessing the stability of preparations in clinical settings.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"44"},"PeriodicalIF":1.2,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11267834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141759343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eggshell membrane and green seaweed (Ulva lactuca) micronized powders for in vivo diabetic wound healing in albino rats: a comparative study. 用于白化大鼠体内糖尿病伤口愈合的蛋壳膜和绿海藻(乳莼)微粉:一项比较研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-23 DOI: 10.1186/s40780-024-00345-x
Moustafa H Moustafa, Mohamed S Turkey, Noha S Mohamedin, Amira A Darwish, Amira A M Elshal, Mona A H Yehia, Mohamed M El Safwany, Ehab I Mohamed

Background: Nonhealing diabetic wounds are a serious complication associated with extremely lethargic wound closure and a high risk of infection, leading to amputation or limb loss, as well as substantial health care costs and a poor quality of life for the patient. The effects of either eggshell membrane (ESM) and green seaweed (Ulva lactuca) extracts alone or in combination were evaluated for in vivo skin wound healing in a rat model of induced diabetes.

Methods: Micronized powders of waste hen ESM, Ulva lactuca, and their 1:1 mixture were prepared using regular procedures. The mechanical, electrical, and surface morphology characteristics of powders were examined using direct compression, LCR-impedancemetry, and scanning electron microscopy. The effect of ESM, Ulva lactuca, and their mixture as compared to standard Dermazin treatments were evaluated on wounds inflicted on male Wistar Albino rats with induced diabetes. Quantitative wound healing rates at baseline and at 3, 7, 14, and 21 days of treatments among all rat groups were conducted using ANOVA. Qualitative histological analysis of epidermal re-epithelization, keratinocytes, basement membrane, infiltrating lymphocytes, collagen fibrines, and blood vessels at day 21 were performed using Image J processing program.

Results: Compressive strength measurements of tablets showed a Young's modulus of 44.14 and 27.17 MPa for the ESM and ESM + Ulva lactuca mixture, respectively. Moreover, both samples exhibited relatively low relative permittivity values of 6.62 and 6.95 at 1 MHz, respectively, due to the porous surface morphology of ESM shown by scanning electron microscopy. On day 21, rats treated with ESM had a complete diabetic wound closure, hair regrowth, and a healing rate of 99.49%, compared to 96.79% for Dermazin, 87.05% for Ulva lactuca, 90.23% for the mixture, and only 36.44% for the negative controls. A well-formed basement membrane, well-differentiated epithelial cells, and regular thick keratinocytes lining the surface of the epidermal cells accompanied wound healing in rats treated with ESM, which was significantly better than in control rats.

Conclusion: Ground hen ESM powder, a low-cost effective biomaterial, is better than Ulva lactuca or their mixture for preventing tissue damage and promoting diabetic wound healing, in addition to various biomedical applications.

背景:糖尿病伤口不愈合是一种严重的并发症,伤口闭合极慢,感染风险高,可导致截肢或肢体缺失,并产生大量医疗费用,患者生活质量低下。本研究评估了蛋壳膜(ESM)和绿海藻(乳莼)提取物单独或混合使用对诱导糖尿病大鼠模型体内皮肤伤口愈合的影响:方法:采用常规程序制备废母鸡ESM、莼菜及其1:1混合物的微粉末。采用直接压缩法、LCR-阻抗测量法和扫描电子显微镜检测了粉末的机械、电学和表面形态特征。在雄性 Wistar Albino 大鼠的诱发糖尿病伤口上评估了 ESM、乳莼及其混合物与标准 Dermazin 处理方法的效果。采用方差分析对各组大鼠在基线和治疗 3、7、14 和 21 天时的伤口愈合率进行了定量分析。使用 Image J 处理程序对第 21 天的表皮再上皮化、角质细胞、基底膜、浸润淋巴细胞、胶原纤维和血管进行定性组织学分析:片剂的抗压强度测量结果显示,ESM 和 ESM + Ulva lactuca 混合物的杨氏模量分别为 44.14 和 27.17 兆帕。此外,由于扫描电子显微镜显示了ESM的多孔表面形态,这两种样品在1 MHz频率下的相对介电常数值分别为6.62和6.95,相对较低。第 21 天,使用 ESM 治疗的大鼠糖尿病伤口完全闭合,毛发再生,愈合率达 99.49%,而 Dermazin 为 96.79%,莼菜为 87.05%,混合物为 90.23%,阴性对照组仅为 36.44%。ESM治疗大鼠的伤口愈合伴随着形成良好的基底膜、分化良好的上皮细胞和表皮细胞表面规则厚实的角质细胞,明显优于对照组大鼠:结论:磨碎的母鸡ESM粉末是一种低成本的有效生物材料,在防止组织损伤和促进糖尿病伤口愈合方面优于乳莼菜或它们的混合物,此外还具有多种生物医学应用价值。
{"title":"Eggshell membrane and green seaweed (Ulva lactuca) micronized powders for in vivo diabetic wound healing in albino rats: a comparative study.","authors":"Moustafa H Moustafa, Mohamed S Turkey, Noha S Mohamedin, Amira A Darwish, Amira A M Elshal, Mona A H Yehia, Mohamed M El Safwany, Ehab I Mohamed","doi":"10.1186/s40780-024-00345-x","DOIUrl":"10.1186/s40780-024-00345-x","url":null,"abstract":"<p><strong>Background: </strong>Nonhealing diabetic wounds are a serious complication associated with extremely lethargic wound closure and a high risk of infection, leading to amputation or limb loss, as well as substantial health care costs and a poor quality of life for the patient. The effects of either eggshell membrane (ESM) and green seaweed (Ulva lactuca) extracts alone or in combination were evaluated for in vivo skin wound healing in a rat model of induced diabetes.</p><p><strong>Methods: </strong>Micronized powders of waste hen ESM, Ulva lactuca, and their 1:1 mixture were prepared using regular procedures. The mechanical, electrical, and surface morphology characteristics of powders were examined using direct compression, LCR-impedancemetry, and scanning electron microscopy. The effect of ESM, Ulva lactuca, and their mixture as compared to standard Dermazin treatments were evaluated on wounds inflicted on male Wistar Albino rats with induced diabetes. Quantitative wound healing rates at baseline and at 3, 7, 14, and 21 days of treatments among all rat groups were conducted using ANOVA. Qualitative histological analysis of epidermal re-epithelization, keratinocytes, basement membrane, infiltrating lymphocytes, collagen fibrines, and blood vessels at day 21 were performed using Image J processing program.</p><p><strong>Results: </strong>Compressive strength measurements of tablets showed a Young's modulus of 44.14 and 27.17 MPa for the ESM and ESM + Ulva lactuca mixture, respectively. Moreover, both samples exhibited relatively low relative permittivity values of 6.62 and 6.95 at 1 MHz, respectively, due to the porous surface morphology of ESM shown by scanning electron microscopy. On day 21, rats treated with ESM had a complete diabetic wound closure, hair regrowth, and a healing rate of 99.49%, compared to 96.79% for Dermazin, 87.05% for Ulva lactuca, 90.23% for the mixture, and only 36.44% for the negative controls. A well-formed basement membrane, well-differentiated epithelial cells, and regular thick keratinocytes lining the surface of the epidermal cells accompanied wound healing in rats treated with ESM, which was significantly better than in control rats.</p><p><strong>Conclusion: </strong>Ground hen ESM powder, a low-cost effective biomaterial, is better than Ulva lactuca or their mixture for preventing tissue damage and promoting diabetic wound healing, in addition to various biomedical applications.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"43"},"PeriodicalIF":1.2,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141752027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Publisher Correction: Comparison of anticoagulation control and outcomes between usual medical care and pharmacist-led anticoagulation service in ambulatory patients taking warfarin at tertiary hospital in Ethiopia: a quasi-experimental study. 出版商更正:埃塞俄比亚三级医院中服用华法林的非住院病人的抗凝控制和疗效:一项准实验研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-19 DOI: 10.1186/s40780-024-00364-8
Tamrat Assefa Tadesse, Amha Gebremedhin, Dejuma Yadeta, Legese Chelkeba, Teferi Gedif Fenta
{"title":"Publisher Correction: Comparison of anticoagulation control and outcomes between usual medical care and pharmacist-led anticoagulation service in ambulatory patients taking warfarin at tertiary hospital in Ethiopia: a quasi-experimental study.","authors":"Tamrat Assefa Tadesse, Amha Gebremedhin, Dejuma Yadeta, Legese Chelkeba, Teferi Gedif Fenta","doi":"10.1186/s40780-024-00364-8","DOIUrl":"10.1186/s40780-024-00364-8","url":null,"abstract":"","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"42"},"PeriodicalIF":1.2,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11258921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141727355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case report of pharmacokinetic analysis of continuous intravenous infusion of fentanyl in a patient with severe burn: burn shock stage complicates pain management. 重度烧伤患者持续静脉注射芬太尼的药代动力学分析病例报告:烧伤休克阶段使疼痛治疗复杂化。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-16 DOI: 10.1186/s40780-024-00363-9
Takafumi Nakano, Yasuhisa Oida, Shinichi Morimoto, Kentaro Muranishi, Soichiro Ushio, Takuya Yamashina, Masanobu Uchiyama, Kenichi Mishima, Kiyoyuki Kitaichi, Yoshihiko Nakamura, Koichi Matsuo

Background: Fentanyl is widely used as an analgesic and sedative for patients with severe burn injuries in intensive care units. However, pharmacokinetic (PK) data for fentanyl, particularly for continuous intravenous infusion during the acute phase of burn injuries, are limited. Here, we report the clinical course and changes in blood fentanyl concentrations during the acute phase in a patient with severe burns treated with continuous intravenous infusion of fentanyl.

Case presentation: A woman in her 40s, with burns caused by a gas cylinder explosion, was transported to our hospital. The patient had burn wounds on face, neck, shoulders, and all four extremities, with a total burn area of 39.0%. For pain relief, the patient received a continuous infusion of 0.01 mg/mL fentanyl (20-30 µg/h) with a target blood concentration of 1.0-1.5 ng/mL, but continued to suffer from pain due to burning during the acute phase. We measured the blood fentanyl concentrations and found that all concentrations obtained during the acute phase were subtherapeutic. Notably, during the burn shock stage, blood concentrations of fentanyl were 0.50 ng/mL on day 1 and 0.66 ng/mL on day 2, indicating that the blood concentration did not rise sufficiently for the dosage. From days 0 to 2, the patient was administered a massive fluid load for burn shock. After the burn shock stage resolved, fentanyl concentrations gradually approached the target range, and the pain rating scale improved, even though the fentanyl administration rate remained unchanged (30 µg/h).

Conclusions: Major changes in the fluid volumes of body compartments that occur with large burns might increase the volume of fentanyl distribution, thereby lowering its concentration when a standard dose is administered. Our findings indicate that the PK of fentanyl in patients with severe burns can be substantially affected, especially during the shock phase, implying the importance of titrating analgesics for clinical efficacy in the acute phase.

背景:芬太尼被广泛用作重症监护室严重烧伤患者的镇痛和镇静剂。然而,芬太尼的药代动力学(PK)数据,尤其是烧伤急性期持续静脉输注芬太尼的数据非常有限。在此,我们报告了一名接受芬太尼持续静脉输注治疗的重度烧伤患者在急性期的临床过程和血液中芬太尼浓度的变化:一名 40 多岁的妇女因煤气罐爆炸导致烧伤被送往我院。患者面部、颈部、肩部和四肢均有烧伤,总烧伤面积达 39.0%。为缓解疼痛,患者接受了 0.01 mg/mL 芬太尼(20-30 µg/h)的持续输注,目标血药浓度为 1.0-1.5 ng/mL,但在急性期仍因烧伤而疼痛难忍。我们测量了血液中的芬太尼浓度,发现在急性期获得的所有浓度都低于治疗浓度。值得注意的是,在烧伤休克阶段,第 1 天和第 2 天的芬太尼血药浓度分别为 0.50 纳克/毫升和 0.66 纳克/毫升,这表明血药浓度的上升不足以满足剂量的需要。从第 0 天到第 2 天,病人因烧伤休克而接受了大量输液。烧伤休克阶段缓解后,芬太尼浓度逐渐接近目标值范围,疼痛评分量表也有所改善,尽管芬太尼给药速度保持不变(30 微克/小时):结论:大面积烧伤时身体各部分液体容量发生的重大变化可能会增加芬太尼的分布容量,从而降低标准剂量给药时的芬太尼浓度。我们的研究结果表明,芬太尼在重度烧伤患者体内的 PK 值会受到很大影响,尤其是在休克期,这意味着在急性期滴定镇痛药以获得临床疗效的重要性。
{"title":"Case report of pharmacokinetic analysis of continuous intravenous infusion of fentanyl in a patient with severe burn: burn shock stage complicates pain management.","authors":"Takafumi Nakano, Yasuhisa Oida, Shinichi Morimoto, Kentaro Muranishi, Soichiro Ushio, Takuya Yamashina, Masanobu Uchiyama, Kenichi Mishima, Kiyoyuki Kitaichi, Yoshihiko Nakamura, Koichi Matsuo","doi":"10.1186/s40780-024-00363-9","DOIUrl":"10.1186/s40780-024-00363-9","url":null,"abstract":"<p><strong>Background: </strong>Fentanyl is widely used as an analgesic and sedative for patients with severe burn injuries in intensive care units. However, pharmacokinetic (PK) data for fentanyl, particularly for continuous intravenous infusion during the acute phase of burn injuries, are limited. Here, we report the clinical course and changes in blood fentanyl concentrations during the acute phase in a patient with severe burns treated with continuous intravenous infusion of fentanyl.</p><p><strong>Case presentation: </strong>A woman in her 40s, with burns caused by a gas cylinder explosion, was transported to our hospital. The patient had burn wounds on face, neck, shoulders, and all four extremities, with a total burn area of 39.0%. For pain relief, the patient received a continuous infusion of 0.01 mg/mL fentanyl (20-30 µg/h) with a target blood concentration of 1.0-1.5 ng/mL, but continued to suffer from pain due to burning during the acute phase. We measured the blood fentanyl concentrations and found that all concentrations obtained during the acute phase were subtherapeutic. Notably, during the burn shock stage, blood concentrations of fentanyl were 0.50 ng/mL on day 1 and 0.66 ng/mL on day 2, indicating that the blood concentration did not rise sufficiently for the dosage. From days 0 to 2, the patient was administered a massive fluid load for burn shock. After the burn shock stage resolved, fentanyl concentrations gradually approached the target range, and the pain rating scale improved, even though the fentanyl administration rate remained unchanged (30 µg/h).</p><p><strong>Conclusions: </strong>Major changes in the fluid volumes of body compartments that occur with large burns might increase the volume of fentanyl distribution, thereby lowering its concentration when a standard dose is administered. Our findings indicate that the PK of fentanyl in patients with severe burns can be substantially affected, especially during the shock phase, implying the importance of titrating analgesics for clinical efficacy in the acute phase.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"41"},"PeriodicalIF":1.2,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of once-daily versus multiple-daily dosing of gentamicin on the incidence of acute kidney injury in patients treated with synergistic combinations of antibiotics. 庆大霉素每日给药一次与每日给药多次对使用协同抗生素组合治疗的患者急性肾损伤发生率的影响。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-15 DOI: 10.1186/s40780-024-00360-y
Kyohei Sugiyama, Keita Hirai, Yukako Suyama, Masato Tsutsumi

Background: Gentamicin is a commonly used antibiotic with synergistic effects that is administered once or multiple times daily. However, the influence of the daily administration frequency on renal function has not yet been identified. This study aimed to investigate the effect of the daily dosing frequency on worsening renal function in patients receiving gentamicin.

Methods: This study included 35 patients undergoing gentamicin treatment who had at least one serum trough level measured and underwent therapeutic drug monitoring (TDM). We evaluated the influence of daily dosing frequency on gentamicin trough concentration and the risk of acute kidney injury (AKI).

Results: Compared to patients who received gentamicin once-daily dosing (n = 22), patients who received multiple-daily dosing (n = 13) had significantly higher initial and minimum trough concentrations after TDM. The proportion of patients with trough concentrations lower than 1.0 µg/mL was significantly higher in the once-daily dosing group at the initial trough concentration, whereas there was no significant difference at the minimum trough concentration after TDM. AKI developed in nine patients; however, there was no significant difference in the incidence of AKI according to the frequency of daily gentamicin dosing. In contrast, a higher minimum trough concentration after TDM was found to be a risk factor for AKI development with an odds ratio of 9.2 (95% confidence intervals; 1.3-65.5).

Conclusion: A higher trough concentration of gentamicin correlated with a higher incidence of AKI. The risk of developing AKI may be reduced by choosing a once-daily dosing regimen or implementing TDM.

背景:庆大霉素是一种具有协同作用的常用抗生素,每天给药一次或多次。然而,每日给药次数对肾功能的影响尚未确定。本研究旨在探讨每日给药次数对接受庆大霉素治疗的患者肾功能恶化的影响:本研究纳入了 35 名接受庆大霉素治疗的患者,他们至少测量了一次血清谷值并接受了治疗药物监测(TDM)。我们评估了每日给药频率对庆大霉素谷浓度和急性肾损伤(AKI)风险的影响:结果:与每日一次服用庆大霉素的患者(22 人)相比,每日多次服用庆大霉素的患者(13 人)在 TDM 后的初始和最低谷浓度明显更高。每日给药一次组患者的初始波谷浓度低于 1.0 µg/mL 的比例明显更高,而 TDM 后的最低波谷浓度则无明显差异。有九名患者出现了 AKI;但是,根据庆大霉素每日给药次数的不同,AKI 的发生率并无明显差异。相反,TDM后的最低谷浓度越高,发生AKI的几率比为9.2(95%置信区间;1.3-65.5):结论:庆大霉素谷浓度越高,AKI发生率越高。结论:较高的庆大霉素谷浓度与较高的 AKI 发生率相关,选择每日一次给药方案或实施 TDM 可降低发生 AKI 的风险。
{"title":"Impact of once-daily versus multiple-daily dosing of gentamicin on the incidence of acute kidney injury in patients treated with synergistic combinations of antibiotics.","authors":"Kyohei Sugiyama, Keita Hirai, Yukako Suyama, Masato Tsutsumi","doi":"10.1186/s40780-024-00360-y","DOIUrl":"10.1186/s40780-024-00360-y","url":null,"abstract":"<p><strong>Background: </strong>Gentamicin is a commonly used antibiotic with synergistic effects that is administered once or multiple times daily. However, the influence of the daily administration frequency on renal function has not yet been identified. This study aimed to investigate the effect of the daily dosing frequency on worsening renal function in patients receiving gentamicin.</p><p><strong>Methods: </strong>This study included 35 patients undergoing gentamicin treatment who had at least one serum trough level measured and underwent therapeutic drug monitoring (TDM). We evaluated the influence of daily dosing frequency on gentamicin trough concentration and the risk of acute kidney injury (AKI).</p><p><strong>Results: </strong>Compared to patients who received gentamicin once-daily dosing (n = 22), patients who received multiple-daily dosing (n = 13) had significantly higher initial and minimum trough concentrations after TDM. The proportion of patients with trough concentrations lower than 1.0 µg/mL was significantly higher in the once-daily dosing group at the initial trough concentration, whereas there was no significant difference at the minimum trough concentration after TDM. AKI developed in nine patients; however, there was no significant difference in the incidence of AKI according to the frequency of daily gentamicin dosing. In contrast, a higher minimum trough concentration after TDM was found to be a risk factor for AKI development with an odds ratio of 9.2 (95% confidence intervals; 1.3-65.5).</p><p><strong>Conclusion: </strong>A higher trough concentration of gentamicin correlated with a higher incidence of AKI. The risk of developing AKI may be reduced by choosing a once-daily dosing regimen or implementing TDM.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"40"},"PeriodicalIF":1.2,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141620219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thiamylal serum concentration for refractory convulsive status epilepticus while associated decreased concentrations of concomitant antiepileptics: a case report. 治疗难治性惊厥性癫痫同时伴有抗癫痫药浓度降低的噻吗洛尔血清浓度:病例报告。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-12 DOI: 10.1186/s40780-024-00362-w
Kazutaka Oda, Tomomi Katanoda, Hitomi Arakaki, Taiki Katsume, Kaho Matsuyama, Hirofumi Jono, Hideyuki Saito

Background: Treating refractory status epilepticus (RSE) remains a challenge. Thiamylal can be used as a second- or third-line treatment; however, its potential to induce cytochrome P450 (CYP) activity may reduce the concentration of antiepileptic drugs (AEDs) administered prior to thiamylal. This report details a case of RSE patient treated with thiamylal, with monitored concentrations of thiamylal and other AEDs.

Case presentation: A 72-year-old healthy man developed RSE. Despite the administration of various AEDs, his seizures were not resolved. Thiamylal was then administered at an initial bolus dose of 2.1 mg/kg, followed by a continuous infusion of 4.2-5.2 mg/kg/h. The initial thiamylal concentration was observed at 7.8 μg/mL, increasing to 35.2 μg/mL before decreasing after dose reduction and cessation. Concurrently, the concentration of concomitant carbamazepine decreased from 5.59 μg/mL to 2.1 μg/mL and recovered as thiamylal concentration decreased. Lesser impacts were noted for other AEDs.

Conclusions: This case report underscored the efficacy of thiamylal in treating RSE. However, it also highlighted the need for clinicians to closely monitor the concentrations of concurrent AEDs, especially carbamazepine, during thiamylal therapy.

背景:治疗难治性癫痫状态(RSE)仍是一项挑战。噻吗洛尔可作为二线或三线治疗药物;然而,其诱导细胞色素P450(CYP)活性的潜力可能会降低在使用噻吗洛尔之前服用的抗癫痫药物(AEDs)的浓度。本报告详细介绍了一例接受噻吗洛尔治疗的 RSE 患者,监测了噻吗洛尔和其他 AEDs 的浓度:一名 72 岁的健康男性出现了 RSE。尽管使用了多种 AEDs,他的癫痫发作仍未得到缓解。随后,以 2.1 毫克/千克的初始栓剂剂量给予噻吗洛尔,然后以 4.2-5.2 毫克/千克/小时的剂量持续输注。观察到噻吗洛尔的初始浓度为 7.8 μg/mL,在减少剂量和停止输注后,浓度升至 35.2 μg/mL,然后又有所下降。与此同时,同时服用的卡马西平浓度从 5.59 μg/mL 降至 2.1 μg/mL,并随着噻吗洛尔浓度的降低而恢复。对其他 AEDs 的影响较小:本病例报告强调了噻吗洛尔治疗 RSE 的疗效。结论:本病例报告强调了噻吗洛尔治疗 RSE 的疗效,但同时也强调了临床医生在噻吗洛尔治疗期间密切监测同时使用的 AEDs(尤其是卡马西平)浓度的必要性。
{"title":"Thiamylal serum concentration for refractory convulsive status epilepticus while associated decreased concentrations of concomitant antiepileptics: a case report.","authors":"Kazutaka Oda, Tomomi Katanoda, Hitomi Arakaki, Taiki Katsume, Kaho Matsuyama, Hirofumi Jono, Hideyuki Saito","doi":"10.1186/s40780-024-00362-w","DOIUrl":"10.1186/s40780-024-00362-w","url":null,"abstract":"<p><strong>Background: </strong>Treating refractory status epilepticus (RSE) remains a challenge. Thiamylal can be used as a second- or third-line treatment; however, its potential to induce cytochrome P450 (CYP) activity may reduce the concentration of antiepileptic drugs (AEDs) administered prior to thiamylal. This report details a case of RSE patient treated with thiamylal, with monitored concentrations of thiamylal and other AEDs.</p><p><strong>Case presentation: </strong>A 72-year-old healthy man developed RSE. Despite the administration of various AEDs, his seizures were not resolved. Thiamylal was then administered at an initial bolus dose of 2.1 mg/kg, followed by a continuous infusion of 4.2-5.2 mg/kg/h. The initial thiamylal concentration was observed at 7.8 μg/mL, increasing to 35.2 μg/mL before decreasing after dose reduction and cessation. Concurrently, the concentration of concomitant carbamazepine decreased from 5.59 μg/mL to 2.1 μg/mL and recovered as thiamylal concentration decreased. Lesser impacts were noted for other AEDs.</p><p><strong>Conclusions: </strong>This case report underscored the efficacy of thiamylal in treating RSE. However, it also highlighted the need for clinicians to closely monitor the concentrations of concurrent AEDs, especially carbamazepine, during thiamylal therapy.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"39"},"PeriodicalIF":1.2,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11245824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141600261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring factors associated with bleeding events after open heart surgery in patients on dialysis - effects of the presence or absence of warfarin therapy. 探讨透析患者开放性心脏手术后出血事件的相关因素--是否接受华法林治疗的影响。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-12 DOI: 10.1186/s40780-024-00353-x
Masanori Suzuki, Yuki Hasegawa, Hiroaki Tanabe, Masayoshi Koinuma, Ryohkan Funakoshi

Background: Perioperative management of patients on dialysis is critical for controlling bleeding and thrombotic risk, in addition to infection control. Postoperative anticoagulation is often difficult to control, and different institutions have different policies. Therefore, in this study, we aimed to investigate factors associated with postoperative bleeding events and whether warfarin (WF) therapy affects the incidence of postoperative bleeding events, total mortality, and stroke.

Methods: Patients who were admitted to the cardiovascular surgery department and underwent valve replacement or plasty were included, and those who underwent mechanical valve introduction were excluded. Thirty-nine patients were included in the study. The primary endpoint was to identify factors associated with the composite endpoint of postoperative bleeding events, and the secondary endpoint was to determine the effect size of WF therapy on postoperative bleeding events, all-cause mortality, and stroke and the strength of association between the crossed endpoints. The strength of the association between the crossed items was examined.

Results: Low body weight (p = 0.038) was identified as a factor associated with the primary endpoint of postoperative bleeding events. The secondary endpoint of whether or not patients received WF therapy was largely unrelated to bleeding events, all-cause mortality, and postoperative stroke up to 90 days after surgery.

Conclusions: Preliminary studies suggest that low body weight is a risk factor for postoperative bleeding events in patients on dialysis, although further exploration of other factors will be necessary with the accumulation of similar cases.

背景:透析患者的围手术期管理对于控制出血和血栓风险以及感染控制至关重要。术后抗凝通常很难控制,不同的机构有不同的政策。因此,在本研究中,我们旨在调查与术后出血事件相关的因素,以及华法林(WF)治疗是否会影响术后出血事件、总死亡率和中风的发生率:纳入心血管外科住院并接受瓣膜置换或成形术的患者,排除接受机械瓣膜置入术的患者。研究共纳入 39 名患者。主要终点是确定与术后出血事件这一复合终点相关的因素,次要终点是确定WF疗法对术后出血事件、全因死亡率和中风的影响大小以及交叉终点之间的关联强度。对交叉项目之间的关联强度进行了研究:结果:低体重(p = 0.038)被确定为与术后出血事件这一主要终点相关的因素。次要终点是患者是否接受 WF 治疗,这与术后 90 天内的出血事件、全因死亡率和术后中风基本无关:初步研究表明,低体重是透析患者术后出血事件的一个危险因素,但随着类似病例的积累,有必要进一步探讨其他因素。
{"title":"Exploring factors associated with bleeding events after open heart surgery in patients on dialysis - effects of the presence or absence of warfarin therapy.","authors":"Masanori Suzuki, Yuki Hasegawa, Hiroaki Tanabe, Masayoshi Koinuma, Ryohkan Funakoshi","doi":"10.1186/s40780-024-00353-x","DOIUrl":"10.1186/s40780-024-00353-x","url":null,"abstract":"<p><strong>Background: </strong>Perioperative management of patients on dialysis is critical for controlling bleeding and thrombotic risk, in addition to infection control. Postoperative anticoagulation is often difficult to control, and different institutions have different policies. Therefore, in this study, we aimed to investigate factors associated with postoperative bleeding events and whether warfarin (WF) therapy affects the incidence of postoperative bleeding events, total mortality, and stroke.</p><p><strong>Methods: </strong>Patients who were admitted to the cardiovascular surgery department and underwent valve replacement or plasty were included, and those who underwent mechanical valve introduction were excluded. Thirty-nine patients were included in the study. The primary endpoint was to identify factors associated with the composite endpoint of postoperative bleeding events, and the secondary endpoint was to determine the effect size of WF therapy on postoperative bleeding events, all-cause mortality, and stroke and the strength of association between the crossed endpoints. The strength of the association between the crossed items was examined.</p><p><strong>Results: </strong>Low body weight (p = 0.038) was identified as a factor associated with the primary endpoint of postoperative bleeding events. The secondary endpoint of whether or not patients received WF therapy was largely unrelated to bleeding events, all-cause mortality, and postoperative stroke up to 90 days after surgery.</p><p><strong>Conclusions: </strong>Preliminary studies suggest that low body weight is a risk factor for postoperative bleeding events in patients on dialysis, although further exploration of other factors will be necessary with the accumulation of similar cases.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"38"},"PeriodicalIF":1.2,"publicationDate":"2024-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11241945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141600260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmaceutical Health Care and Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1